Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABEO 
Abeona Therapeutics Inc (ABEO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ABEO (1-star) is a SELL. SELL since 2 days. Simulated Profits (-2.87%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20.5
1 Year Target Price $20.5
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.99% | Avg. Invested days 40 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 293.57M USD | Price to earnings Ratio 8.95 | 1Y Target Price 20.5 |
Price to earnings Ratio 8.95 | 1Y Target Price 20.5 | ||
Volume (30-day avg) 6 | Beta 1.67 | 52 Weeks Range 3.93 - 7.54 | Updated Date 09/16/2025 |
52 Weeks Range 3.93 - 7.54 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14310.5% | Operating Margin (TTM) -5698% |
Management Effectiveness
Return on Assets (TTM) -24.5% | Return on Equity (TTM) 48.34% |
Valuation
Trailing PE 8.95 | Forward PE 22.57 | Enterprise Value 128279005 | Price to Sales(TTM) 733.92 |
Enterprise Value 128279005 | Price to Sales(TTM) 733.92 | ||
Enterprise Value to Revenue 320.7 | Enterprise Value to EBITDA 1.6 | Shares Outstanding 51278500 | Shares Floating 38195333 |
Shares Outstanding 51278500 | Shares Floating 38195333 | ||
Percent Insiders 5.78 | Percent Institutions 73.57 |
Upturn AI SWOT
Abeona Therapeutics Inc
Company Overview
History and Background
Abeona Therapeutics Inc. was founded in 1974 as Hemispherx Biopharma, Inc, then restructured as PlasmaTech Biopharmaceuticals, Inc. in 2014. It changed its name to Abeona Therapeutics Inc. in 2015 and focuses on developing gene and cell therapies for severe diseases.
Core Business Areas
- Gene and Cell Therapies: Develops gene and cell therapies for rare genetic diseases.
Leadership and Structure
Jou00e3o Siffert, M.D. serves as Chief Executive Officer and is supported by a management team with expertise in drug development and gene therapy. The company operates with a typical corporate structure including a Board of Directors overseeing operations.
Top Products and Market Share
Key Offerings
- ABO-102: AAV-based gene therapy for Sanfilippo syndrome type A (MPS IIIA). Has received orphan drug and rare pediatric disease designations. No clear market share or revenue data available. Competitors include Lysogene (no US ticker) and Orchard Therapeutics (no US ticker).
- EB-101: Gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). Granted RMAT designation from the FDA and orphan drug designation. Competitors include Krystal Biotech (KRYS) and Castle Creek Biosciences.
Market Dynamics
Industry Overview
The gene and cell therapy market is rapidly growing, driven by technological advancements and increasing regulatory approvals. The industry is characterized by high R&D costs and potential for high rewards for successful therapies.
Positioning
Abeona is a clinical-stage biopharmaceutical company focused on gene and cell therapies for rare diseases. They are positioned as an innovator in this space.
Total Addressable Market (TAM)
The gene therapy market is projected to reach billions of dollars. Abeona is focused on niche rare disease markets, aiming to capture a significant portion of these sub-markets.
Upturn SWOT Analysis
Strengths
- Proprietary gene therapy platform
- Orphan drug designations for multiple programs
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- High R&D costs
- No currently marketed products
Opportunities
- Potential FDA approval of EB-101
- Expansion of pipeline with new gene therapy programs
- Partnerships with larger pharmaceutical companies
- Growing market for gene and cell therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene therapy companies
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- KRYS
Competitive Landscape
Abeona faces intense competition from established and emerging gene therapy companies. Its competitive advantage lies in its specific disease targets and proprietary technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancements in clinical trials and expansion of the pipeline.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates are variable due to the inherent risks in drug development.
Recent Initiatives: Recent initiatives include advancing the EB-101 clinical program and exploring new gene therapy targets.
Summary
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on gene and cell therapies for rare diseases, which makes the risk higher. It is working on innovative products but is dependent on successful clinical trials and funding. The potential FDA approval of EB-101 is a key milestone. Abeona needs to secure funding and partnerships and it must navigate regulatory hurdles in the future to be successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered as investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abeona Therapeutics Inc
Exchange NASDAQ | Headquaters Cleveland, OH, United States | ||
IPO Launch date 1980-09-19 | President, CEO & Director Dr. Vishwas Seshadri M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 136 | |
Full time employees 136 | |||
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.